Abstract
INTRODUCTION
In the past decade, transcatheter aortic valve implantation (TAVI) has been consolidated as an established treatment option for patients with severe symptomatic aortic stenosis and is meanwhile approved for use in intermediate to high surgical risk or inoperable patients. Transfemoral (TF) access is the preferred delivery route, as sheaths have substantially decreased in diameter, allowing the procedure in the majority of patients [1] [2] [3] . If TF delivery is not possible, transapical (TA) delivery is the most common access route, accounting for 9% of implantations in a recent European Association of Percutaneous Cardiovascular Interventions (EAPCI) survey and for nearly 3000 implants per year in Germany [1, 2] .
Currently, only 2 transcatheter heart valve (THV) types are commercially available for TA delivery: the balloon-expandable Edwards Sapien XT and Sapien 3 (Edwards LifeSciences LLC, Irvine, CA, USA) and the self-expanding Symetis ACURATE TA and ACURATE neo TM (Symetis SA, a Boston Scientific company, Ecublens, Switzerland). While the ACURATE neo formerly was only compatible with TF delivery, a novel delivery system now also allows for an antegrade TA access route. In contrast to the current TF system, the TA system offers the option of resheathing and repositioning or retrieval of the THV, potentially enhancing both procedural safety and functional results. Furthermore, the size of the TA delivery system was reduced from 33 Fr to 22 Fr outer diameter (19 Fr inner diameter).
We aimed to assess the safety and performance of this novel device in high-risk patients with severe aortic stenosis.
METHODS

Study design and population
The ACURATE neo TA study is a prospective, single-arm, multicentre study conducted at 7 centres in Germany. Main inclusion criteria were severe aortic stenosis defined as mean aortic gradient >40 mmHg, or peak jet velocity >4.0 m/s, or aortic valve area of <0.8 cm 2 ; multidisciplinary heart team consensus that patient is at high risk for conventional aortic valve replacements [Society of Thoracic Surgeons (STS) score > _8% or other comorbid conditions unrelated to aortic stenosis]; multidisciplinary heart team consensus that the TA approach is the most suitable access route; New York Heart Association (NYHA) functional class >II; aortic annulus diameter > _21 mm and < _27 mm measured by computed tomography (CT) or transoesophageal echocardiography and signed informed consent. Main exclusion criteria were congenital unicuspid or bicuspid aortic valve or non-calcified, extreme eccentricity of calcification; severe mitral regurgitation (>3+); preexisting prosthetic heart valve or ring or left ventricular ejection fraction <20% by echocardiography. The full list of inclusion and exclusion criteria is provided at ClinicalTrials.gov #NCT02950428. Follow-up visits including echocardiographic examinations were scheduled at discharge or 7 days, whichever occurred first, at 30 days and at 6 and 12 months. Annually from 2 to 5 years after the procedure, a telephone contact is scheduled to assess adverse events, NYHA class and antiplatelet therapy.
The study was conducted according to the Declaration of Helsinki and was approved by the central ethics committees and competent authorities; all patients provided written informed consent prior to any study procedure. Monitoring included 100% source document verification, except for fluoroscopy time and amount of contrast that were evaluated retrospectively. The study was supervised by a data safety monitoring board, a clinical events committee adjudicated all clinical end points and echocardiographic assessments were analysed by an independent echocardiography core laboratory.
Study device and procedure
The ACURATE neo self-expanding THV has been described previously [4, 5] . It is seated supra-annular, and its leaflets are made of porcine pericardium. The stabilization arches orient the prosthesis during deployment to obtain stable positioning and better coaxial alignment. The valve opens from top to bottom, unsheathing the upper crown and the stabilization arches in a first step and, in a second step, the lower crown to anchor the device inside the annulus. The outer and inner pericardial skirts prevent direct contact of stent struts with the surrounding tissue within the left ventricular outflow tract and are designed to prevent paravalvular leakage (PVL). The prosthesis is partially repositionable before deployment step 2 is initiated and allows treatment of aortic annulus diameters from 21 mm to 27 mm. The ACURATE neo TA delivery system (Supplementary Material, Fig. S1 ) has a flexible inner member that contains a guidewire lumen bonded proximally onto a female luer lock and distally to a radiopaque atraumatic tip, a safety knob to avoid premature release of the prosthesis and a radiopaque markerband for accurate positioning of the prosthesis. A further asymmetric radiopaque markerband indicates the position of one of the bioprosthesis commissural posts when loaded onto the delivery system to allow for anatomically correct commissure-to-commissure axial alignment The ACURATE neo gained CE certification in 2014 and the ACURATE neo TA delivery system in June 2017.
The implantation followed standard practice. The recommended medication regimen is acetylsalicylic acid lifelong (100 mg/day) and dual antiplatelet therapy with clopidogrel 75 mg/day for 6 months after the procedure.
End points and definitions
The primary safety end-point was all-cause mortality at 6-month follow-up, and the primary performance end-point was procedural success in the absence of major adverse cardiac and cerebrovascular events (MACCE) at 30 days. Procedural success was defined as ACURATE neo at the intended location with aortic regurgitation <3+, mean aortic gradient <20 mmHg, effective orifice area (EOA) > _1.0 cm 2 , no further reintervention on the ACURATE neo implant within 24 h of procedure and no intraprocedural mortality. Secondary end points were device success, all-cause mortality at 30 days and 12 months, freedom from MACCE, standardized clinical end points according to the Valve Academic Research Consortium guidelines 2 at 30 days [6] , NYHA functional improvement and valve performance determined by echocardiographic assessment (mean aortic gradient, EOA, aortic regurgitation and left ventricular ejection fraction). Device success was defined as a single-study device implanted at the intended location, no impingement of the mitral valve, normal coronary blood flow, aortic regurgitation <Grade 3+, mean aortic gradient <20 mmHg, EOA > _1.0 cm 2 and no further reintervention on the ACURATE neo implant within 24 h. MACCE was defined as composite of death, myocardial infarction, reintervention and stroke.
Statistical analysis
There was no formal statistical hypothesis. The sample size was arbitrarily selected so as to give an initial assessment of the new device in this exploratory study. For quantitative variables, means and standard deviations (SDs) and for categorical data, absolute and relative frequencies were calculated. When appropriate, confidence intervals (CIs) for proportions were derived using the Wilson method. For clinical outcomes, Kaplan-Meier estimates were calculated and corresponding CIs using the log-log transform. Data analysis was performed using SAS V9.4 (SAS Institute, Cary, NC, USA).
RESULTS
From November 2015 until October 2016, 60 patients were enrolled. Data at 30 days are available for all patients and at 6 months for all, except 1 patient who withdrew consent. The mean age of patients was 79.8 ± 4.7 years, and predominant comorbidities were hypertension (83.3%), coronary artery disease (71.7%), arrhythmias (51.7%), diabetes (38.3%), peripheral artery disease (35.0%), renal failure (25.0%), porcelain aorta (23.3%) and chronic obstructive pulmonary disease (21.7%) ( Table 1) . According to the prespecified inclusion and exclusion criteria, all patients were deemed to be ineligible for a retrograde TF access, mostly due to a previous diagnosis of peripheral artery disease or due to heavily calcified and/or small-calibre peripheral vasculature as detected in the planning CT.
Procedural details are described in Table 2 . A non-rib spreading approach using soft tissue retractors only was used in 88.3% of patients (n = 53). Predilatation was performed in nearly all patients (n = 57, 95%). Resheathing was performed in 4 patients to correct the initial malpositioning (6.7%), and post-dilatation was performed in 35 (58.3%) patients due to residual PVL. Balloon diameters ranged from 20 mm to 26 mm. Device implantation time, defined as the apical introduction of the delivery system to removal post-implantation, was 3 ± 2 min. Device success was obtained in all patients, and procedural success in all but 1 patient (98.3%) who died intraprocedure. A partial tear-out of 1 purse string was noted after the removal of the delivery system, and the patient went on cardiopulmonary bypass with cannulation of the left femoral artery and the right femoral vein. While the apical tear was closed with additional sutures, after a few minutes, there was no cardiac output. It was assumed that the absence of cardiac output was due to a staged retrograde dissection of the heavily calcified left iliac artery ascending to the descending aorta. The patient subsequently died. Procedural success in the absence of MACCE at 30 days was 90.0% (n = 54).
The mean length of stay was 11.5 ± 6.7 days. Through 30 days, 4 additional patients died (1 due to heart failure, 2 due to pneumonia and 1 with sepsis and prolonged delirium), leading to a 30-day mortality estimate of 8.3% (95% CI 1.1-15.1). Clinical outcomes are provided in Table 3 . One minor stroke occurred through 30 days. Aside from the apex tear described above, one further major vascular complication, an occlusion of the right common femoral artery at day 7, was observed. A troponin T rise at day 5 without evidence of acute ischaemia was adjudicated as myocardial infarction. Permanent pacemaker implantation was necessary in 10 patients [17.2% (95% CI 6.9-26.3)]; thereof 8 patients had pre-existing conduction disorders or a history of arrhythmia (including 5 patients with atrial fibrillation, 1 patient with atrial fibrillation and right bundle branch block, 1 patient with left bundle branch block and 1 patient with a history of left anterior hemiblock, right bundle branch block and first-degree atrioventricular block). Four additional patients died until the 6-month follow-up (1 sudden unwitnessed death, 1 due to spontaneous myocardial infarction, 1 due to arrhythmia and 1 due to end-stage renal failure) (Fig. 1) .
Echocardiographic parameters are displayed in Table 4 . The EOA improved from 0.7 ± 0.2 cm 2 at baseline to 1.8 ± 0.5 cm 2 at 30 days and 1.9 ± 0.5 cm 2 at 6 months. No PVL > _2+ was observed at 30 days, but 4.4% (2/45) at 6 months. Both patients had a Grade 1 PVL at 30-day follow-up.
NYHA class improved over time. All patients were in NYHA Class III/IV at baseline; at 30 days, 79.2% (38/48) and at 6 months, 89.8% (44/49) of patients were in NYHA Class I/II (Fig. 2) .
DISCUSSION
This is the first report of a novel, low-profile TA delivery system in combination with the self-expandable ACURATE neo THV. The results indicate good clinical and performance outcomes despite use in a high-risk patient population not suitable for TF therapy.
Given that the vast majority of patients in current clinical practice are treated via the TF approach [1, 2] , the logistic EuroSCORE I of 20.9% in our series is somewhat surprising as it might have been expected that patients selected for TA access would have an even higher mean risk. However, patients had high rates of comorbidities that may not have been adequately captured in the logistic EuroSCORE, particularly atherosclerotic diseases such as coronary artery disease (71.7%) and porcelain aorta (23.3%). Similarly, the 'non-TF' arm of the SOURCE 3 registry (including 72% of patients with TA access) had a logistic EuroSCORE I of 21.8%, which was also similar to the precursor SOURCE XT registry. Rates of atherosclerotic diseases were comparable to our series and significantly higher compared to patients receiving TF-TAVI [7] .
Procedure
The device implantation time of only 3 ± 2 min was short and indicates ease and simplicity of the 2-step deployment system. Compared to its precursor, the ACURATE neo TA delivery system offers the possibility to resheath the prosthesis. This functionality was used in 4 procedures to correct the initial THV malpositioning. The high rate of post-dilatation (58.3%) may be partially attributed to the early device experience but more likely is attributed to the low radial force of the device. In the SAVI-TF registry using the same device, a post-dilatation rate of 44.8% was observed [8] . Moreover, a high valvular calcium load of this contemporary TA patient cohort may have contributed to an increased need for post-dilatation. 
CATHETER-BASED VALVE OPERATIONS
Despite the higher post-dilatation rate compared to balloon expandable valves, the fluoroscopy time (7.0 min) and amount of contrast (100.4 ml) were similar to 'non-TF patients' treated with the SAPIEN 3 prosthesis with fluoroscopy times ranging from 6.8 to 8.2 min and amount of contrast ranging from 87.7 to 97.5 ml [7, 9] .
Mortality
The observed mortality is higher than that anticipated by the logistic EuroSCORE II and STS scores. As discussed before, risk scores are known to not adequately capture the true risk of this population. While the low patient number hampers the comparison, the observed mortality rate is within the expected range and similar to those obtained with the SAPIEN 3 THV that exhibited 30-day mortality rates of 11.9% in the 54 'non-TF' patients of the CE-mark cohort, 4.0% in 252 'non-TF' patients of the SOURCE 3 registry and 5.4% in high-risk 'non-TF' patients of the SAPIEN 3 US trial [7, 9, 10] . Notably, the SAPIEN 3 US trial found that, in intermediate-risk patients, there was no difference in 30-day mortality between TF and non-TF patients, suggesting that TA access is better tolerated in lower risk patients [10] .
Major vascular complications
The reduction to 22 Fr outer diameter for all device sizes accompanied by increasing operator experience likely led to better outcomes compared to studies using the precursor 33 Fr device [5] . In the present series, only 1 apical access complication occurred, indicating an increased safety profile using this novel low-profile catheter.
Permanent pacemaker implantation
The pacemaker rate of 17.2% (95% CI 6.9-26.3) is surprising, as pacemaker rates for the ACURATE neo THV using TF access were 10.3% in the TF89 CE-mark cohort and 8.3% in the SAVI-TF 1000 registry [8, 11] . In a recent multicentre study that used pre-and post-dilatation balloon diameters 1-3 mm smaller than the perimeter-derived annular diameter, the 30-day pacemaker rate was even as low as 2.3% [12] .
Furthermore, the pacemaker rate is higher compared to the precursor ACURATE TA THV, which had pacemaker rates of 11.1% in the TA90 cohort and of 10.2% in the SAVI TA registries [4, 13] . This is contraintuitive, as the ACURATE neo has a lower radial strength compared to its precursor. Specifically, in a singlecentre registry, the pacemaker rate was 16.5% for patients treated via TA access using the ACURATE TA THV versus 9.6% for patients treated via TF access using the ACURATE neo THV. The authors discussed that the difference might be caused by different baseline characteristics of TA versus TF patients or by the higher radial strength of the ACURATE TA THV [5] .
There are several factors that might have impacted the pacemaker rate in our series. First, there was a high arrhythmia rate at baseline. Right bundle branch block, bradycardia, atrioventricular block and atrial fibrillation are known predictors for pacemaker implantation [14] [15] [16] , and only 2 of the 10 patients with pacemaker implants up to 30 days did not have any baseline arrhythmia/conduction defects. Second, the high post-dilatation rate of >50% could have influenced the pacemaker rate, but the postdilatation rate was not higher than for the above-mentioned TF studies [8, 11] . Third, the high pacemaker rate could be a bychance finding attributed to the low patient number with wide CIs (95% CI 6.9-26.3) at 30 days.
Echocardiographic outcomes
ACURATE neo has a supra-annular design potentially resulting in larger EOAs and lower mean gradients compared to SAPIEN 3 (EOAs at 30 days of 1.8 cm 2 compared to 1.5 m 2 and 1.7 cm 2 for SAPIEN 3 and mean gradient of 5.9 mmHg compared to 10.6 mmHg and 11.4 mmHg) [9, 10] . No moderate or severe PVL was observed at 30 days, but there were 2 cases of moderate PVL at 6 months. An increased rate at 6 months compared to earlier time points is surprising, but measurement of PVL is not precise and has limitations, particularly in supra-annular prostheses and during early post-procedural assessments [17] .
In summary, the ACURATE neo TA system is an important addition to the current TAVI armamentarium, as it is the only self-expanding supra-annular prosthesis with TA access. Patients with smaller annuli may particularly benefit from a supra-annular THV and patients with heavy calcification of the left ventricular outflow tract may benefit from reduced risk for complications such as annular rupture.
Limitations
This study has several limitations. First, it is of exploratory nature with a relatively small sample size resulting in wide CIs around the estimates of event rates. There was no CT core laboratory, no systematic quantification or assessment of calcium load and no assessment of LVOT calcification. This information would have been potentially useful in understanding the cases where pacemaker implantation was required. Finally, the study was conducted only in Germany and local practice might differ from other geographies. A planned post-market registry including more patients will provide further insight into event rates.
CONCLUSION
This study indicates the safety and performance of TA-TAVI using the novel low-profile ACURATE neo TA delivery system in combination with the ACURATE neoTHV. High device and procedural success, short implantation times and a low rate of access siterelated complications underline the good safety profile and ease of implantation.
